Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 161 pages | ID: E377196A5AABEN
Global Markets Direct

Abstracts

Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Drugs In Development, 2022, provides an overview of the Endometriosis (Women's Health) pipeline landscape.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 13, 8, 19, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.

Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).
• The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Endometriosis - Overview
Endometriosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Endometriosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Endometriosis - Companies Involved in Therapeutics Development
Endometriosis - Drug Profiles
Endometriosis - Dormant Projects
Endometriosis - Discontinued Products
Endometriosis - Product Development Milestones
Featured News & Press Releases
Oct 26, 2022: Enteris BioPharma announces acceptance of abstract for oral presentation at ASRM 2022 Scientific Congress & Expo
Jun 17, 2022: Myovant Sciences and Pfizer announce publication in The Lancet of phase 3 SPIRIT 1 and SPIRIT 2 studies of once-daily Relugolix combination therapy in women with endometriosis-associated pain
Jun 14, 2022: Enteris BioPharma presents data from two clinical studies involving oral formulations of leuprolide at ENDO 2022 Annual Conference
May 25, 2022: ObsEva presents clinical data on oral GnRH antagonist linzagolix at multiple congresses
May 09, 2022: Ironwood Pharmaceuticals to present new IW-3300 data at Digestive Disease Week 2022
May 09, 2022: FDA extends review period for Pfizer-Myovant’s sNDA for Myfembree
Apr 28, 2022: BioInvent receives milestone payment from Bayer/Hope Medicine licensing agreement
Apr 12, 2022: Enteris BioPharma announces acceptance of two abstracts for presentation at ENDO 2022 Annual Conference
Apr 12, 2022: Myovant Sciences and Pfizer provide update on supplemental new drug application for MYFEMBREE for the management of moderate to severe pain associated with endometriosis
Mar 22, 2022: ObsEva announces additional efficacy results for linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
Jan 06, 2022: ObsEva announces positive topline results for Linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial in patients with moderate-to-severe endometriosis-associated pain
Dec 10, 2021: ObsEva hosts symposium and presents clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
Dec 02, 2021: ObsEva announces symposium and presentation of clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
Oct 19, 2021: Myovant Sciences and Pfizer present data on Relugolix combination therapy from studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
Oct 04, 2021: Enteris BioPharma announces successful completion of phase 1 clinical trial of optimized Peptelligence oral leuprolide
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Endometriosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Endometriosis - Pipeline by Abalone Bio Inc, 2022
Endometriosis - Pipeline by Aptorum Group Ltd, 2022
Endometriosis - Pipeline by Bayer AG, 2022
Endometriosis - Pipeline by BCI Pharma SA, 2022
Endometriosis - Pipeline by Bol Pharma, 2022
Endometriosis - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Endometriosis - Pipeline by Context Therapeutics Inc, 2022
Endometriosis - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Endometriosis - Pipeline by Egret Therapeutics Inc, 2022
Endometriosis - Pipeline by Eikonoklastes Therapeutics Inc, 2022
Endometriosis - Pipeline by ElexoPharm GmbH, 2022
Endometriosis - Pipeline by Endomet Biosciences Inc, 2022
Endometriosis - Pipeline by Enteris BioPharma Inc, 2022
Endometriosis - Pipeline by Eurofarma Laboratorios SA, 2022
Endometriosis - Pipeline by Evestra Inc, 2022
Endometriosis - Pipeline by Evotec SE, 2022
Endometriosis - Pipeline by Ferring International Center SA, 2022
Endometriosis - Pipeline by Forendo Pharma Ltd, 2022
Endometriosis - Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
Endometriosis - Pipeline by Hangzhou Metai Pharmaceutical Technology Co Ltd, 2022
Endometriosis - Pipeline by Hope Medicine Inc, 2022
Endometriosis - Pipeline by Immunitor Inc, 2022
Endometriosis - Pipeline by Insud Pharma, 2022
Endometriosis - Pipeline by Ironwood Pharmaceuticals Inc, 2022
Endometriosis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Endometriosis - Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Endometriosis - Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
Endometriosis - Pipeline by Medibiofarma SL, 2022
Endometriosis - Pipeline by Mithra Pharmaceuticals SA, 2022
Endometriosis - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Endometriosis - Pipeline by Myovant Sciences Ltd, 2022
Endometriosis - Pipeline by Navad Life Sciences Pte Ltd, 2022
Endometriosis - Pipeline by Nippon Shinyaku Co Ltd, 2022
Endometriosis - Pipeline by Predictive Therapeutics LLC, 2022
Endometriosis - Pipeline by PregLem SA, 2022
Endometriosis - Pipeline by SYNG Pharmaceuticals Inc, 2022
Endometriosis - Pipeline by Synokem Pharmaceuticals Ltd, 2022
Endometriosis - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Endometriosis - Pipeline by Temple Therapeutics BV, 2022
Endometriosis - Pipeline by TiumBio Co Ltd, 2022
Endometriosis - Pipeline by ValiRx Plc, 2022
Endometriosis - Pipeline by Viramal Ltd, 2022
Endometriosis - Pipeline by Xbrane Biopharma AB, 2022
Endometriosis - Dormant Projects, 2022
Endometriosis - Dormant Projects, 2022 (Contd..1)
Endometriosis - Dormant Projects, 2022 (Contd..2)
Endometriosis - Dormant Projects, 2022 (Contd..3)
Endometriosis - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Endometriosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022